Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine

  • Alexander BechererEmail author
  • Georgios Karanikas
  • Monica Szabó
  • Georg Zettinig
  • Susanne Asenbaum
  • Christine Marosi
  • Christine Henk
  • Patrick Wunderbaldinger
  • Thomas Czech
  • Wolfgang Wadsak
  • Kurt Kletter
Molecular Imaging


Imaging of amino acid transport in brain tumours is more sensitive than fluorine-18 2-fluoro-deoxyglucose positron emission tomography (PET). The most frequently used tracer in this field is carbon-11 methionine (MET), which is unavailable for PET centres without a cyclotron because of its short half-life. The purpose of this study was to evaluate the performance of 3,4-dihydroxy-6-[18F]fluoro-phenylalanine (FDOPA) in this setting, in comparison with MET. Twenty patients with known supratentorial brain lesions were referred for PET scans with FDOPA and MET. The diagnoses were 18 primary brain tumours, one metastasis and one non-neoplastic cerebral lesion. All 20 patients underwent PET with FDOPA (100 MBq, 20 min p.i.), and 19 of them also had PET scans with MET (800 MBq, 20 min p.i.). In all but one patient a histological diagnosis was available. In 15 subjects, histology was known from previous surgical interventions; in five of these patients, as well as in four previously untreated patients, histology was obtained after PET. In one untreated patient, confirmation of PET was possible solely by correlation with MRI; a histological diagnosis became available 10 months later. MET and FDOPA images matched in all patients and showed all lesions as hot spots with higher uptake than in the contralateral brain. Standardised uptake value ratios, tumour/contralateral side (mean±SD), were 2.05±0.91 for MET and 2.04±0.53 for FDOPA (NS). The benign lesion, which biopsy revealed to be a focal demyelination, was false positive, showing increased uptake of MET and FDOPA. We conclude that FDOPA is accurate as a surrogate for MET in imaging amino acid transport in malignant cerebral lesions for the purpose of visualisation of vital tumour tissue. It combines the good physical properties of 18F with the pharmacological properties of MET and might therefore be a valuable PET radiopharmaceutical in brain tumour imaging.


18F-fluorodopa Brain tumour imaging Amino acid transport Positron emission tomography 



This research was supported by Lord Mayor of Vienna grant 1863/00.


  1. 1.
    Hoh CK, Schiepers C, Seltzer MA, et al. PET in oncology: will it replace the other modalities? Semin Nucl Med 1997; 27:94–106.PubMedGoogle Scholar
  2. 2.
    Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med 1999; 40:591–603.PubMedGoogle Scholar
  3. 3.
    Delbeke D. Oncological applications of FDG PET imaging. J Nucl Med 1999; 40:1706–1715.PubMedGoogle Scholar
  4. 4.
    Di Chiro G, DeLaPaz RL, Brooks RA, et al. Glucose utilization of cerebral gliomas measured by [18F]fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32:1323–1329.PubMedGoogle Scholar
  5. 5.
    Di Chiro G, Brooks RA, Patronas NJ, et al. Issues in the in vivo measurement of glucose metabolism of human central nervous system tumors. Ann Neurol 1984; 15:S138–S146.PubMedGoogle Scholar
  6. 6.
    Derlon JM, Bourdet C, Bustany P, et al. [11C]l-methionine uptake in gliomas. Neurosurgery 1989; 25:720–728.PubMedGoogle Scholar
  7. 7.
    De Witte O, Goldberg I, Wikler D, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001; 95:746–750.PubMedGoogle Scholar
  8. 8.
    Ericson K, Lilja A, Bergstrom M, et al. Positron emission tomography with ([11C]methyl)-l-methionine, [11C]d-glucose, and [68Ga]EDTA in supratentorial tumors. J Comput Assist Tomogr 1985; 9:683–689.Google Scholar
  9. 9.
    Bustany P, Chatel M, Derlon JM, et al. Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C11-l-methionine. J Neurooncol 1986; 3:397–404.PubMedGoogle Scholar
  10. 10.
    Bergstrom M, Collins VP, Ehrin E, et al. Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 1983; 7:1062–1066.Google Scholar
  11. 11.
    Lilja A, Bergstrom K, Hartvig P, et al. Dynamic study of supratentorial gliomas withl-methyl-11C-methionine and positron emission tomography. AJNR Am J Neuroradiol 1985; 6:505–514.PubMedGoogle Scholar
  12. 12.
    Ogawa T, Shishido F, Kanno I, et al. Cerebral glioma: evaluation with methionine PET. Radiology 1993; 186:45–53.PubMedGoogle Scholar
  13. 13.
    Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-l-tyrosine for tumor imaging. J Nucl Med 1999; 40:205–212.PubMedGoogle Scholar
  14. 14.
    Weber WA, Wester HJ, Grosu AL, et al. O-(2-[18F]fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000; 27:542–549.PubMedGoogle Scholar
  15. 15.
    Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983; 305:137–138.PubMedGoogle Scholar
  16. 16.
    Nahmias C, Garnett ES, Firnau G, Lang A. Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci 1985; 69:223–230.PubMedGoogle Scholar
  17. 17.
    Leenders KL, Frackowiak RS, Lees AJ. Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. Brain 1988; 111:615–630.PubMedGoogle Scholar
  18. 18.
    Gupta N, Bradfield H. Role of positron emission tomography scanning in evaluating gastrointestinal neoplasms. Semin Nucl Med 1996; 26:65–73.PubMedGoogle Scholar
  19. 19.
    Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E.18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001; 28:64–71.Google Scholar
  20. 20.
    Hoegerle S, Altehoefer C, Ghanem N, et al. Whole-body18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 2001; 220:373–380.PubMedGoogle Scholar
  21. 21.
    Heiss WD, Wienhard K, Wagner R, et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med 1996; 37:1180–1182.PubMedGoogle Scholar
  22. 22.
    Schmitz F, Plenevaux A, Del Fiore G, Lemaire C, Comar D, Luxen A. Fast routine production of l-[11C-methyl]methionine with Al2=3/KF. Appl Radiat Isot 1995; 46:893–897.CrossRefGoogle Scholar
  23. 23.
    de Vries EFJ, Luurtsema G, Bruessermann M, Elsinga PH, Vaalburg W. Fully automated synthesis module for the high yield one-pot preparation of 6-[18F]fluoro-l-DOPA. Appl Radiat Isot. 1999; 51:389–349.Google Scholar
  24. 24.
    Oldendorf WH, Szabo J. Amino acid assignment to one of three blood-brain barrier amino acid carriers. Am J Physiol 1976; 230:94–98.PubMedGoogle Scholar
  25. 25.
    O'Tuama LA, Guilarte TR, Douglass KH, et al. Assessment of [11C]-l-methionine transport into the human brain. J Cereb Blood Flow Metab 1988; 8:341–345.Google Scholar
  26. 26.
    Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998; 39:778–785.PubMedGoogle Scholar
  27. 27.
    Bader JB, Samnick S, Moringlane JR, et al. Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. Eur J Nucl Med 1999; 26:144–151.PubMedGoogle Scholar
  28. 28.
    Goldman S, Levivier M, Pirotte B, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 1997; 38:1459–1462.PubMedGoogle Scholar
  29. 29.
    Voges J, Herholz K, Holzer T, et al.11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotact Funct Neurosurg 1997; 69:129–135.PubMedGoogle Scholar
  30. 30.
    Herholz K, Holzer T, Bauer B, et al.11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998; 50:1316–1322.PubMedGoogle Scholar
  31. 31.
    Roelcke U, Radu E, Ametamey S, Pellikka R, Steinbrich W, Leenders KL. Association of rubidium and C-methionine uptake in brain tumors measured by positron emission tomography. J Neurooncol 1996; 27:163–171.PubMedGoogle Scholar
  32. 32.
    Nakagawa M, Kuwabara Y, Sasaki M, et al.11C-methionine uptake in cerebrovascular disease: a comparison with 18F-fDG PET and 99mTc-HMPAO SPECT. Ann Nucl Med 2002; 16:207–211.PubMedGoogle Scholar
  33. 33.
    Becherer A, Szabó M, Asenbaum S, Marosi C, Angelberger P, Kletter K.18F-DOPA as a surrogate for 11C-methionine in non-invasive diagnosis of brain tumours [abstract]. Eur J Nucl Med 2002; 29:S7.Google Scholar
  34. 34.
    Fuchtner F, Angelberger P, Kvaternik H, Hammerschmidt F, Simovc BP, Steinbach J. Aspects of 6-[18F]fluoro-l-DOPA preparation: precursor synthesis, preparative HPLC purification and determination of radiochemical purity. Nucl Med Biol 2002; 29:477–481.CrossRefPubMedGoogle Scholar
  35. 35.
    Eriksson B, Bergstrom M, Orlefors H, Sundin A, Oberg K, Langstrom B. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med 2000; 44:68–76.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Alexander Becherer
    • 1
    Email author
  • Georgios Karanikas
    • 1
  • Monica Szabó
    • 1
  • Georg Zettinig
    • 1
  • Susanne Asenbaum
    • 2
  • Christine Marosi
    • 3
  • Christine Henk
    • 4
  • Patrick Wunderbaldinger
    • 4
  • Thomas Czech
    • 5
  • Wolfgang Wadsak
    • 1
  • Kurt Kletter
    • 1
  1. 1.Department of Nuclear Medicine, Medical SchoolUniversity of ViennaViennaAustria
  2. 2.Department of Neurology, Medical SchoolUniversity of ViennaViennaAustria
  3. 3.Department of Oncology, Medical SchoolUniversity of ViennaViennaAustria
  4. 4.Department of Radiology, Medical SchoolUniversity of ViennaViennaAustria
  5. 5.Department of Neurosurgery, Medical SchoolUniversity of ViennaViennaAustria

Personalised recommendations